Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 1.00 |
| ▸ | CHUK | O15111 | 16/20 | 1.00 |
| ▸ | CDK11B | P21127 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 2/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 1.00 |
| ▸ | CDK11A | Q9UQ88 | 2/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | MAPK7 | Q13164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-345541 SCHEMBL29670419 | 1.00 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| Bms-345541 SCHEMBL14141907 | 0.99 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| Bms-345541 SCHEMBL30120667 | 0.99 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL25735941 | 0.89 | IKBKB (0.80) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL17995389 | 0.77 | IKBKB (0.62) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL20440096 | 0.76 | BRD4 (0.69) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL14431616 | 0.76 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL18344276 | 0.74 | IKBKB (0.59) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL31069482 | 0.74 | IKBKB (0.59) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL14431694 | 0.74 | IKBKB (0.69) | IKBKBCHUKCDK11BCDK7CDK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113174387-B | Hydrogel immobilized microorganism preservation method | 浙江海洋大学 | 2022-12-02 | — | — | CN | claimed |
| CN-113174387-A | Hydrogel immobilized microorganism preservation method | 浙江海洋大学 | 2021-07-27 | — | — | CN | claimed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | claimed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | claimed |
| US-12268690-B2 | Treatments for mutations in acute myeloid leukemia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240033265-A2 | TREATMENTS FOR MUTATIONS IN ACUTE MYELOID LEUKEMIA | OREGON HEALTH & SCIENCE UNIVERSITY | 2024-02-01 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023092094-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20040086896-A1 | Polynucleotides and polypeptides associated with the NF-kB pathway | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| WO-2002060386-A3 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL MYERS SQUIBB CO (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | IKBKB 3547/4885CHUK 3193/4885CDK11B 1986/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | IKBKB 824/4885CHUK 657/4885CDK11B 514/4885 |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | NFKBIA, IKBKG, IKBKB | IKBKB 3/4885CHUK 6/4885CDK11B 1030/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | IKBKB 3/4885CHUK 4/4885CDK11B 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.